Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on uniQure (QURE – Research Report), retaining the price target of $70.00.
Patrick Trucchio has given his Buy rating due to a combination of factors influencing uniQure’s stock. Despite recent concerns about the appointment of a new head at the FDA’s Center for Biologics Evaluation and Research (CBER) and mixed competitor data, Trucchio remains optimistic about uniQure’s prospects. The company’s lead gene therapy candidate, AMT-130, for Huntington’s disease, has shown strong data and received positive feedback from Key Opinion Leaders, which supports a favorable regulatory outcome.
Furthermore, the FDA’s recent grant of Breakthrough Therapy designation to AMT-130 enhances confidence in an accelerated approval pathway. This designation allows for intensive guidance and interaction with senior FDA managers, aligning with the positive interim data from AMT-130’s Phase 1/2 trials. Trucchio believes that the sell-off of uniQure’s stock is overdone and maintains a $70 price target, expecting no significant delays in AMT-130’s clinical development and a potential commercial launch in 2026.
In another report released on April 29, Leerink Partners also maintained a Buy rating on the stock with a $48.00 price target.
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of QURE in relation to earlier this year.